ORGANIZATION

• Policymakers Prod for Industry’s Concrete Actions Toward Eliminating Drug Loss
  April 24, 2024

• Govt Should Buy Up Domestic Antibiotic APIs, Cost 5-8 Times Higher: Industry Official
  April 24, 2024

• JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
  April 19, 2024

• Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
  April 18, 2024

• Only 3 Prefectures Log “Below 80%” Generic Rate in November: Kyokai Kenpo
  April 10, 2024

• JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
  April 9, 2024

• New LLP Coverage Scheme Intended for Generic Promotion: Payer Exec
  April 8, 2024

• Generic Rate Hits Record for 6th Straight Quarter in October-December: JGA
  April 8, 2024

• PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
  April 4, 2024

• Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
  April 3, 2024

• Wholesaler Group Launches Database for Unit Price-Based Negotiations
  April 2, 2024

• Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
  March 26, 2024

• FPMAJ Lays Out Planned Activities for FY2024
  March 22, 2024

• Scrap Off-Year Drug Revision as It Mars Innovation, Supply: JPMA Official
  March 22, 2024

• Shipments Restricted or Halted for 26.6% of Drugs in February: FPMAJ
  March 21, 2024

• Biosafety Rules Tied to Gene Therapy Put Heavy Financial Burden on Hospitals: Expert
  March 19, 2024

• Doctors’ Groups Call for Cross-Ministerial Efforts to Spur Genomic Medicine
  March 18, 2024

• JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief
  February 19, 2024

• Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
  February 19, 2024

• Payers, HCPs Hail First Step Taken for Generic Industry Revamp in FY2024 Reform
  February 15, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• …
• Next ›
• 最終 »